The MHRA issued a botulinum toxin safety advisory this summer that a surprising number of clinic owners I've spoken to hadn't seen. The Legal 500's September 2026 review of aesthetics regulation describes the current compliance picture as "an increasingly complex regulatory landscape", which is the kind of restrained language lawyers use when they mean things have got genuinely difficult.
Two developments are worth your attention right now: the ASA's shift to AI-assisted advertising monitoring, and updated MHRA guidance on botulinum toxin products. They're separate issues with separate consequences, but both landed in the same month and both require something from you this week, not next quarter.
What the ASA's AI Monitoring Actually Does
The ASA has moved away from relying solely on public complaints to flag non-compliant ads. Their monitoring system now scans digital content, including paid social, websites, and influencer posts, at a scale that wasn't possible before. The practical effect is that ads which would previously have sat unnoticed unless a competitor or patient reported them are now being caught proactively.
For aesthetics clinics this matters more than for most sectors. The advertising rules around prescription-related treatments (which include botulinum toxin under the Human Medicines Regulations 2012) are strict. You cannot advertise a prescription-only medicine to the public. What counts as advertising, though, is broader than most clinic owners assume. Before-and-after photos with captions that imply a specific treatment, "book your Botox" call-to-action buttons, and certain promotional offers have all been found non-compliant in previous ASA rulings.
The AI system doesn't just look at obvious adverts. It reads context. A post framed as educational that consistently links to a booking page for a specific prescription treatment is the kind of thing that previously slipped through. That's less reliable now.
What to review this week
Pull your last 90 days of Instagram, Facebook, and TikTok posts. Look for anything that names a prescription treatment and includes a price, a promotional offer, or a direct booking link. Check your Google Ads copy. Check your website's treatment pages for language that reads as an invitation to self-refer for a prescription product rather than a consultation.
The ASA's own guidance on advertising botulinum toxin and dermal fillers is publicly available on their website. It's worth reading the current version, not the one you found in a 2022 training slide deck, because the application of these rules has tightened.
If you work with influencers or patient ambassadors, any content they post about specific treatments you've provided is likely to be considered an ad by the ASA, and the responsibility partly sits with you. They need to label it. You should have that conversation now and get it in writing.
The MHRA Botulinum Toxin Advisory
The specific MHRA warning from this period relates to unlicensed botulinum toxin products entering the supply chain. The concern is counterfeit or substandard product being sold to clinics, sometimes through channels that look legitimate.
This is not a new problem, but the MHRA's renewed advisory signals active enforcement attention. Buying from an unauthorised wholesaler, even unknowingly, puts you in a difficult position: regulatory exposure, potential product liability, and if something goes wrong with a patient, an almost impossible insurance situation.
Checking your supply chain
The MHRA maintains a register of licensed wholesale dealers for human medicines. Your botulinum toxin supplier should appear on it. If you're not certain your current supplier is on the register, check the GOV.UK MHRA list today, not at your next stock order.
Some clinics have ended up with unlicensed product because a rep offered a significantly lower price than market rate. If you've received an unusually cheap quote recently, that's worth treating as a warning sign. The licensed distributors for botulinum toxin products in the UK are a fairly small group and their pricing doesn't vary wildly.
Keep your purchase records. The lot numbers, the supplier invoices, the delivery confirmations. If the MHRA ever asks, or if a patient complication leads to a product inquiry, you need to be able to show exactly what you bought and from whom.
The Broader Compliance Shift
The Legal 500 piece is worth reading in full if you haven't. Its argument, roughly, is that aesthetics regulation in 2026 is no longer primarily about whether you have the right qualifications on the wall. Enforcement is becoming multi-agency and more automated. The ASA, MHRA, CQC (where applicable), and local authority licensing schemes are all active simultaneously, and they don't coordinate in ways that make life easy for clinics.
The practical consequence is that a clinic can be fully compliant on one axis and badly exposed on another. Good practitioners with legitimate qualifications who are buying from licensed suppliers can still run Google Ads that breach the CAP Code without realising it. And vice versa.
HealSuite keeps supplier and product records attached to treatment logs, which at least means the documentation side of the MHRA question is easier to manage. But no software fixes a compliance gap you haven't identified yet.
One Thing I Think Clinics Are Getting Wrong
Most compliance conversations I have with clinic owners focus on what might happen. The ASA will probably not come after us. The MHRA is probably looking at someone else. That's been a reasonable working assumption for years, because enforcement was slow and complaint-driven.
The AI monitoring changes that assumption for advertising, specifically. It's not that the rules changed. It's that the probability of being caught changed. A post that was 95% likely to go unnoticed last year might now be 60% likely to be flagged. That's a different risk calculation.
I don't know where the MHRA's enforcement attention is actually focused right now. I'd be making that up. What I do know is that the advisory came out for a reason, and unlicensed product in the supply chain is a documented problem, not a theoretical one.
The clinics most at risk from both of these issues are the ones that are busy and assume someone else on the team is handling it. That's worth checking before the week is out.